Date: 2013-05-31
Type of information: Initiation of development program
phase:
Announcement: initiation of development program
Company: XBiotech (USA - TX)
Product: True Human™ therapeutic antibody neutralizing interleukin-6 (IL-6)
Action
mechanism: monoclonal antibody
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On May 31, 2013, XBiotech announced its development of a novel True Human™ therapeutic antibody. The Company reports that the antibody neutralizes a pro-inflammatory molecule known as interleukin-6 (IL-6). Agents targeting IL-6 have been effective therapy for a number of autoimmune or oncology-related diseases. Other therapeutic antibody products targeting IL-6 have already reached clinical trials and the market place, but the Company believes that its antibody will represent a substantial improvement over these existing agents. True Human™ antibodies, which are cloned directly from a human immune response, are expected to be the safest, best tolerated antibody therapeutics. The Company is now developing a manufacturing process for the antibody, and expects to be ready for clinical studies in early 2014.
